Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy Transcript
Seeking Alpha·2025-12-11 06:02
PresentationWelcome to Medicenna Therapeutics KOL Webinar. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, please disconnect at this time. I'd now like to turn the call over to Dr. Fahar Merchant, President and CEO.Fahar MerchantFounder, Chairman, President & CEO Good morning, good afternoon, everyone, and thank you for joining us today. My name is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. We are thrilled to welcome you to thi ...